Drug intelligence / Profile preview

DXP-604

Development stage: Phase 2
Lead developer: Singlomics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

DXP-604 is a human monoclonal antibody developed by Singlomics Biopharmaceuticals and BeiGene as a neutralizing agent against SARS-CoV-2, the virus responsible for COVID-19. It targets the spike (S) protein of SARS-CoV-2 and acts by blocking the interaction between the viral S protein and the ACE2 receptor on host cells, thereby preventing viral entry. Preclinical studies have shown that DXP-604 has broad-spectrum antiviral activity with high potency against multiple variants of SARS-CoV-2, including Delta and Omicron. Clinical trials have demonstrated its ability to accelerate recovery in hospitalized patients with mild to moderate COVID-19 symptoms and reduce inflammatory markers in high-risk patients.

Other names: BGB-DXP-604BGB-DXP604BGB-DXP 604

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on DXP-604.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DXP-604.

Explore the full profile